

B² cont
36.1 (Once amended) A composition for sensitizing cells of a mammal so as to enhance insulin uptake and/or utilization of glucose by the cells comprising:
(a) a therapeutically effective amount of a sulfonylurea; and,
(b) a therapeutically effective amount of one or more insulin sensitizers to sensitize the cells of the mammal so as to enhance insulin uptake and/or utilization of glucose by the cells of the mammal thus reducing the therapeutic dose required of the sulfonylurea.

B³
40.11 (Once amended) A composition for sensitizing cells of a mammal so as to enhance insulin uptake and/or utilization of glucose by the cells comprising:
(a) a therapeutically effective amount of a biguanide; and,
(b) a therapeutically effective amount of one or more insulin sensitizers to sensitize the cells of the mammal so as to enhance insulin uptake and/or utilization of glucose by the cells of the mammal thus reducing the therapeutic dose required of the biguanide.

B⁴
45.14 (Once amended) A composition for sensitizing cells of a mammal so as to enhance insulin uptake and/or utilization of glucose by the cells comprising:
(a) a therapeutically effective amount of an alpha-glucosidase inhibitor; and,
(b) a therapeutically effective amount of one or more insulin sensitizers to sensitize the cells of the mammal so as to enhance insulin uptake and/or utilization of glucose by the cells of the mammal thus reducing the therapeutic dose required of the alpha-glucosidase inhibitor.

B⁵
49.20 (Once amended) A method for sensitizing cells of a mammal so as to enhance insulin uptake and/or utilization of glucose by the cells comprising administering to the mammal a therapeutic amount of an insulin sensitizer with a therapeutic amount of an orally ingestible anti-diabetic agent, where
(1) the insulin sensitizer is selected from the group consisting of: BRL-49653, Pioglitazone HCL, Troglitazone, MC 555, ALRT 268, LGD 1069, Chromic Picolinate and V-411; and